Related Experiment Video

Updated: Feb 12, 2026

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
05:35

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Published on: September 15, 2023

2.1K

Pharmacogenomic progress in individualized dosing of key drugs for cancer patients

Christine M Walko1, Howard McLeod

  • 1Division of Pharmacotherapy and Experimental Therapeutics, North Carolina School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599-7360, USA.

Nature Clinical Practice. Oncology
|January 29, 2009
PubMed

Insights

Personalizing chemotherapy dosing using pharmacogenomics can overcome challenges with current body surface area calculations. This approach aims to reduce toxicity and improve treatment effectiveness for cancer patients.

Area of Science:

  • Pharmacology
  • Genetics
  • Oncology

Background:

  • Chemotherapy dosing relies on body surface area, which poorly predicts drug response.
  • Most chemotherapeutic agents have a narrow therapeutic index, making dosing difficult.

Purpose of the Study:

  • To review limitations of current chemotherapy dosing.
  • To explore pharmacogenomics for personalized cancer therapy.
  • To highlight how genetic variations impact drug metabolism and efficacy.

Main Methods:

  • Review of existing literature on chemotherapy dosing and pharmacogenomics.
  • Analysis of genetic differences in drug-metabolizing enzymes.
  • Examination of clinical studies demonstrating pharmacogenomic applications.

Main Results:

  • Body surface area dosing is inadequate for many chemotherapeutic agents.
  • Genetic variations in drug-metabolizing enzymes explain significant pharmacokinetic variability.
  • Pharmacogenomic studies show promise in reducing toxicity and improving efficacy.

Conclusions:

  • Individualizing chemotherapy based on pharmacogenomics can optimize treatment outcomes.
  • Pharmacogenomic-directed therapy offers a path to minimize toxicity and maximize efficacy.
  • Future research in pharmacogenomics will guide personalized cancer pharmacotherapy.

More Related Videos

Establishment of Gastric Cancer Patient-derived Xenograft Models and Primary Cell Lines08:42

Establishment of Gastric Cancer Patient-derived Xenograft Models and Primary Cell Lines

Published on: July 19, 2019

10.7K
Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment09:56

Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment

Published on: April 30, 2019

9.6K

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
278
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
324
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
269
Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
290
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
231
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K